No significant impact on relapse free survival was observed in a large cohort of younger adult AML patients (Gaidzik et al., 2012) and no difference in relapse incidence at 5 years in CN-AML patients with or without TET2 mutations (Ahn et al., 2015), whilst other studies demonstrated that TET2 mutations were correlated with inferior outcomes in favorable-risk CN-AML (Patel et al., 2012) and failure to achieve complete remission in childhood AML (Kutny et al., 2015). The gene discussed is TET2; the disease is acute myeloid leukemia.